NCT00364026View on ClinicalTrials.gov

A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

June 30, 2004

Study Completion Date

July 31, 2005

Conditions

Hypertension

Interventions

DRUG

darusentan

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT00364026 - A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs | Biotech Hunter | Biotech Hunter